Peptide half-lives: what determines how long a compound stays active

Half-life is the time required for the concentration of a substance in the bloodstream to fall to half of its previous level. It is a foundational concept in pharmacokinetics because it shapes how often a dose needs to be repeated to sustain a given level of exposure, and how much a substance's concentration swings between doses. The NIH's clinical pharmacology overview frames half-life as one of the first values considered when designing any dosing schedule, alongside how the drug is absorbed, distributed, and cleared [1]. A peptide with a half-life of a few hours behaves very differently across a day than one with a half-life measured in days, and that difference in behavior is what this article is about.

Three structural factors mostly determine a peptide's half-life. Molecular size matters because the kidneys filter small molecules out of the blood efficiently; peptides under roughly 5 kilodaltons clear renally faster than larger ones. Resistance to enzymatic breakdown matters because blood and tissue contain proteases that cleave peptide bonds, and an unmodified, natural peptide sequence can be degraded within minutes of entering circulation. Binding to plasma proteins, particularly albumin, matters because a peptide that reversibly attaches to a large, slowly-cleared protein is effectively shielded from filtration and enzymatic attack for as long as it stays bound. These three factors, independently or in combination, explain most of the difference between a peptide that lasts minutes and one engineered to last days.

Concrete examples make the range easier to grasp, and it is worth being precise about where each number actually comes from, since these figures vary by species and by study. BPC-157, an unmodified short peptide, was studied in a pharmacokinetic paper in Frontiers in Pharmacology that measured an elimination half-life under 30 minutes across both rats and dogs following intravenous administration, specifically around 15 minutes in rats and roughly 5 minutes in beagle dogs, with the compound becoming undetectable in plasma within about 4 hours [2]. This is animal pharmacokinetic data; the paper does not report a validated human half-life, which is a meaningful limitation given how often BPC-157 is discussed in the context of human use.

Semaglutide illustrates deliberate half-life engineering. A 2015 paper in the Journal of Medicinal Chemistry describes how its developers extended the molecule's duration of action by increasing its affinity for albumin, building on the earlier once-daily GLP-1 analogue liraglutide to produce a compound suitable for once-weekly dosing, with a half-life of approximately one week in humans [3]. Tirzepatide, a related dual GIP/GLP-1 receptor agonist, has a population pharmacokinetic half-life of approximately 5 days based on modeling across nearly 5,800 participants in 19 pooled clinical studies, also enabled by high albumin binding [4]. CJC-1295, a modified growth-hormone-releasing hormone analogue, shows the clearest example of how a single modification changes everything: a 2006 study in the Journal of Clinical Endocrinology & Metabolism found that when CJC-1295 is linked to a Drug Affinity Complex (DAC), which allows it to covalently bind circulating albumin, its estimated half-life becomes 5.8 to 8.1 days in healthy adults, compared with roughly 30 minutes for the unmodified peptide without that modification [5]. Same core sequence, dramatically different pharmacokinetics, purely from one structural change.

Steady state is the point in repeated dosing where the amount entering the body with each dose balances the amount being cleared, so average concentration levels off rather than continuing to rise. This generally takes about four to five half-lives to reach under a consistent dosing schedule [1]. For a compound with a roughly week-long half-life, that translates to something on the order of four to five weeks before exposure has fully stabilized at a given dose, which is a reasonable general basis for why clinical evaluation of such compounds tends to wait for a period before judging effect at a given dose, rather than adjusting after a few days. For a compound with a half-life of minutes to hours, steady state, and equally, full washout after stopping, happens much faster.

A common misconception is that half-life and duration of effect are the same thing; they are not, and the mismatch can be substantial when a drug triggers a downstream signaling cascade that outlasts the drug's presence in blood. Bremelanotide (marketed as Vyleesi and studied under the research designation PT-141) is FDA-approved for hypoactive sexual desire disorder in premenopausal women based on the RECONNECT phase 3 trials published in Obstetrics & Gynecology in 2019 [6]. Its plasma half-life is short, but its melanocortin-receptor activation initiates a signaling cascade that continues after the drug itself has been substantially cleared, which is a documented general property of receptor-mediated signaling rather than something unique to this molecule; this article does not restate a specific duration-of-effect figure here because that number is a matter for the product's own clinical labeling and a prescriber, not a general pharmacokinetics discussion. The broader point, that plasma half-life describes clearance of the molecule itself, not necessarily how long downstream biological effects persist, holds across many receptor-targeted peptides and is one reason half-life alone cannot answer every practical question about a compound's behavior.

The practical difference between short and long half-lives cuts both ways rather than making one category simply better. A short half-life means a compound's effects and any adverse effects clear relatively quickly if something needs to be reconsidered, but it generally requires more frequent dosing to sustain a given level of exposure. A long half-life supports a simpler, less frequent schedule, but it also means that adjusting course, whether due to a side effect or any other reason, takes longer to play out, since the compound continues acting on the body for an extended stretch after any change is made.

Evidence quality: the general pharmacokinetic principles of half-life and steady state are Strong Human Evidence, standard clinical pharmacology taught and applied across essentially all drug classes [1]. The specific half-life figures for semaglutide, tirzepatide, and CJC-1295 with DAC come from Strong Human Evidence in the form of published human pharmacokinetic and clinical trial data [3][4][5]. The BPC-157 half-life figure is Animal Research only, from rat and dog studies, with no validated human pharmacokinetic data available in the peer-reviewed literature [2], which is a genuine and important gap given how widely that compound is discussed in a human-use context. Bremelanotide's approved use and trial data represent Strong Human Evidence for its approved indication [6], though the specific duration-of-effect claims sometimes made about it online exceed what the cited trial data directly establishes.

Species differences add another layer of uncertainty that is worth naming directly rather than glossing over. Pharmacokinetic values measured in rats or dogs, as with the BPC-157 figures above, do not automatically transfer to humans; clearance mechanisms, enzyme activity, and plasma protein composition all differ across species, sometimes substantially. Where a compound's only published pharmacokinetic data comes from animal studies, the honest position is that its human half-life is not established, rather than assuming the animal figure applies directly, or worse, assuming a longer or shorter value without any data at all.

Route of administration and formulation also interact with half-life in ways that are easy to overlook when comparing figures across different peptides. A subcutaneous injection typically produces a slower rise and a somewhat different clearance profile than an intravenous dose of the same molecule, because absorption from the injection site becomes a rate-limiting step that intravenous administration bypasses entirely; this is part of why the BPC-157 intravenous figures cited above should not be read as directly describing subcutaneous injection, which is the route most commonly discussed for that peptide outside laboratory settings. Similarly, extended-release or depot formulations of an otherwise short-half-life molecule can produce a much longer apparent duration of action by slowing absorption from the injection site, independent of any change to the molecule's intrinsic plasma clearance once absorbed. Reading a half-life figure without checking which route and formulation it was measured under is a common way these numbers get misapplied.

For anyone trying to make sense of a protocol involving multiple compounds, the practical use of half-life information is mostly about calibrating expectations and patience: knowing that a long-half-life compound requires weeks, not days, to show its full stabilized effect at a given dose, and that a short-half-life compound's effects and side effects will resolve quickly if something is not working. The actual dosing interval, frequency, and any changes to a regimen are decisions for a treating clinician who has considered the specific compound, the individual's health history, and the intended goal, not a generic schedule derived from a half-life number alone.